Alembic Pharmaceuticals: General Updates: Updated Details of Key Managerial Personnel
Alembic Pharmaceuticals (APLLTD) filed a disclosure titled "General Updates: Updated Details of Key Managerial Personnel". The company is valued at about ₹17,966 crore.
What happened
Alembic Pharmaceuticals (APLLTD) filed a disclosure with the exchanges on 4 November 2026 at 03:11 PM titled "General Updates: Updated Details of Key Managerial Personnel".
Company snapshot
Alembic Pharmaceuticals is a small-cap company in the Healthcare sector, with a market value of about ₹17,966 crore.
The stock last traded at ₹914, against a 52-week range of ₹635.8–₹998 (8.4% below the high).
Before this filing the shares had moved −1.5% over the month and −0.8% over three months. Average daily turnover over the last 20 sessions was about ₹8.65 crore.
Promoters held 69.87% at the end of Q1 FY27, up 0.13% points from the previous quarter. Foreign institutions owned 4.18% and domestic institutions 15.94%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 1,711 | 154.4 | 7.85 |
| Q2 FY26 | 1,910 | 184.7 | 9.4 |
| Q3 FY26 | 1,876 | 133 | 6.76 |
| Q4 FY26 | 1,848 | 201.5 | 10.31 |
| Q1 FY27 | 2,150 | 173.1 | 8.8 |
What history shows
This is not the company's first management change disclosure: BCEIE has 7 earlier filings of this kind on record since May 2026.
After those filings, the stock gained 2.3% on average the next trading day and was up 1.6% on average after five days (6 filings with price data).
Across 114 similar disclosures by other Healthcare companies, shares moved +0.9% on average the next day and +1.8% over five days; 46% of them rose the next day.
Market-wide, 4,237 management change filings with an impact score of 50 or more saw an average next-day move of −0.1%, with 44% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 10 Aug 2026 | Management change | +1.2% | −0.8% |
| 18 Jun 2026 | Management change | +4.1% | +2.9% |
| 18 Jun 2026 | Management change | +4.1% | +2.9% |
| 3 Jun 2026 | Management change | +2.1% | +1.5% |
| 2 Jun 2026 | Management change | +1.7% | +1.6% |
What to watch
- The appointment of a successor and any change in strategy or guidance.
- 4 November 2026: Board meeting — Financial Results/Other business matters.
In the news
Recent coverage elsewhere (links open the original publisher):
- Alembic Pharmaceuticals Limited Estimates – NSE:APLLTD
- Pradeep Jain Appointed Associate Vice President – Accounts & Finance at Alembic Pharmaceuticals
- Alembic Pharmaceuticals Receives USFDA Approval for Venetoclax Tablets
- Alembic Pharmaceuticals Limited (APLLTD.NS) Seasonal returns chart
- Alembic Pharmaceuticals receives USFDA final approval for Venetoclax tablets
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.